Navigation Links
Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Company's Ongoing Phase I/II Trial in Acute Myeloid Leukemia
Date:9/7/2012

NEW YORK, Sept. 7, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with two times higher activity of the Company's investigational new drug Actimab-A. 

"This is a significant milestone for our company," commented Jack Talley, CEO of Actinium Pharmaceuticals. "Our program is now advancing rapidly, offering new hope for patients who were until now generally considered untreatable, as additional leading cancer treatment centers continue to join our trial." 

The trial is a prospective, open-label study, designed to determine the safety and efficacy of Actimab-A in newly diagnosed AML patients who cannot tolerate current high dose chemotherapeutic regimens. 

Mr. Talley added, "Acute myeloid leukemia in patients over the age of 60 is a serious unmet need and we are eager to make this treatment available to patients."

Actimab-A is being developed using Company's proprietary patented APIT technology and it consists of the monoclonal antibody Lintuzumab used to guide the alpha emitting radioisotope actinium 225 to malignant cells.

About actinium 225

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed.  The technology was first demonstrated by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center. 

About Lintuzumab (HuM195)

Lintuzumab is a monoclonal a
'/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
3. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, ... announced that its Chairman and CEO, Alan Shortall ... 26th Annual Healthcare Conference at the New York Palace ... 2014. The conference presentation will be ... Webcast. To listen, please go to: http://ir.unilife.com/events.cfm . ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... SAN DIEGO , Nov. 25, 2014 Halozyme ... at the Piper Jaffray Healthcare Conference in New ... p.m. EDT/10:00 a.m. PDT . Dr. Helen Torley ... overview. The presentation will be webcast through the ... and a recording will be made available for 90 days ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... devices to a concussion management system for athletes, Cleveland Clinic,s ... and approaches to treating a host of medical conditions. ... by a panel of Cleveland Clinic physicians and scientists and ... The Top 10 Medical Innovations for 2012 are: ...
... from a heart attack is more than a fear among people ... The mortality and morbidity rates for heart disease among those ... Ohio, according to federal and state data. But with ... that will soon change. The federal grant will be used to ...
Cached Medicine Technology:Cleveland Clinic Unveils Top 10 Medical Innovations for 2012 2Cleveland Clinic Unveils Top 10 Medical Innovations for 2012 3Cleveland Clinic Unveils Top 10 Medical Innovations for 2012 4Grant Will Help Save Lives in Appalachian Ohio 2
(Date:11/26/2014)... Deaf teens have stronger language and reading skills if their ... study suggests. Researchers looked at a group of deaf ... through an infant screening program conducted in the 1990s. ... those who were screened by the time they were 9 ... children who weren,t screened as infants. This new study ...
(Date:11/26/2014)... Nov. 26, 2014 (HealthDay News) -- New regulations to ... plants and factories were issued Wednesday by the U.S. ... asthma, heart disease and premature death. The new ... from 75 parts per billion to between 65 to ... ozone pollution standards in line with the latest science ...
(Date:11/26/2014)... 2014 The report “Laboratory Information ... (On-premise, Hosted, SaaS), End User Labs (Clinical, Molecular ... (Software, Services) - Global Forecast to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ... forecasts of the revenue and market growth. , ...
(Date:11/26/2014)... Increasing demand for diagnostic imaging ... surgeries has paved way for consequent increase in ... various types of cancers and cardiac diseases globally ... for these owing to their use in diagnosing ... market can also be attributed to advancements in ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Gone are the ... cheap deals on Black Friday, which signifies the beginning of ... items into their shopping carts in the comfort of their ... , This Friday is going to be an occasion ... day, with an estimated $2.48 billion in revenue for online ...
Breaking Medicine News(10 mins):Health News:Spotting Hearing Problems in Infancy May Boost Reading Skills in Deaf Teens 2Health News:EPA Issues Tougher Rules on Ozone Emissions 2Health News:EPA Issues Tougher Rules on Ozone Emissions 3Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:2014 Best Friday Deals Revealed by Top10InAction 2
... breakthrough, which could eventually lead to a practical and cost ... the US National Cancer Institute have genetically modified bacteria living ... infection. // ,Most HIV transmission occurs on the ... coated with a layer of bacteria. ,The researchers ...
... Minister Anbumani Ramadoss on Saturday urged the State Government ... 80-year-old Communicable Diseases Hospital (CDH) in Tondiarpet in north ... wards in the hospital, Anbumani told journalists that though ... controlling the cholera outbreak in the city post-rains, the ...
... a 17-year-old teenager named Daniel Hindle of Carvale Drive, Richmond, ... the verdict of 'death by misadventure.' // ,Daniel died ... lip pierced in a salon in the city. He was ... fever. Commenting on the verdict, South Yorkshire coroner ...
... LINK Applied Genomics Programme has proved to be a ... diagnose meningitis, MRSA and Chlamydia; has regenerated spinal nerve ... and has provided effective vaccines against Salmonella. This programme ... collaboration with 23 industrial partners to identify new methods ...
... global problem, the entire world is struggling against the ... as opposed to traditional foods.,Eating patterns are undergoing a ... about this fast food generation growing up. ... to launch a poster campaign to shock children away ...
... bird flu may reduce world energy demand should it evolve ... by more than 1-million barrels a day//. ,World oil ... issued by the US Energy Information Administration. “Should the ... would be profound, potentially reducing energy demand by well over ...
Cached Medicine News:Health News:Genetically modified bacteria to combat HIV 2Health News:Diligence Of Chennai Doctors Appreciated: Anbumani 2Health News:LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems 2Health News:Bird Flu Likely To Reduce World Energy Demand 2
... Brachial Index (ABI) is one of the most simple to perform and useful vascular tests for assessing ... to perform a complete ABI. ... ... ...
... Auto Refractor/Keratometer. Advanced engineering, rapid ... illumination mode make it the most ... 5.5 inch High Quality Monitor ... Rapid, instantaneous readings are taken as ...
A fully automated, benchtop instrument designed for high-volume urine testing, using Siemens' proven technology in dry-pad urine chemistry analysis....
A fully automated, benchtop instrument designed for high-volume urine testing, using Siemens' proven technology in dry-pad urine chemistry analysis....
Medicine Products: